Vertex Pharmaceuticals is strutting toward its Q1 earnings report with a 22.3% stock surge this year, brushing up against its 52-week high. While analysts expect a dip in earnings per share, revenue ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

Raised in a farming area in central Illinois, Dr. Scarlett is a native Midwesterner and has lived in five heartland states. He earned a medical degree at the ...

The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

UMass Lowell Recognized as Top Research Institution with R1 Classification Read More ⁠ ...

How could a non-opioid painkiller improve the lives of people with chronic pain? What makes a non-opioid painkiller safer ...

The FDA has approved suzetrigine, a groundbreaking painkiller that blocks sodium channels to provide opioid-level pain relief without the risks of addiction, sedation, or overdose. Known as ...

On 30 January 2025, the US Food and Drug Administration (FDA) approved the non-opioid medication suzetrigine (JOURNAVX), which was developed by Vertex Pharmaceuticals for moderate to severe acute ...

The decision roused excitement across the healthcare sector for a key reason: the drug, which is called suzetrigine and sold under the brand name Journavx, is not an opioid.

Suzetrigine (Journavx) shows promise as a non-addictive pain treatment, offering systemic relief without opioid-related side effects, but faces Tier 3 insurance hurdles. Financially strong with a ...